Prevention of cancer by inhibiting aging

被引：83

作者：

Blagosklonny, Mikhail V. ^{[1
,2
]}

机构：

[1] Ordway Res Inst, Ctr Canc, Albany, NY 12208 USA

[2] Oncotarget, Albany, NY USA

来源：

CANCER BIOLOGY & THERAPY | 2008年 / 7卷 / 10期

关键词：

cancer; aging; rapamycin; metformin; mTOR; calorie restriction; senescence;

D O I：

10.4161/cbt.7.10.6663

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aging is associated with cancer, in particular with breast, prostate, colon, lung, stomach, bladder and skin cancer. This article discusses how aging predisposes one to cancer. In principle, inhibition of aging should delay cancer. But is it possible to slow aging? As recently proposed, the nutrient-sensing TOR ( target of rapamycin) pathway is involved in cellular and organismal aging. In rodents, certain conditions that interfere with the TOR pathway slow aging and prevent cancer. Retrospective analysis of clinical data reveals that inhibitors of TOR prevent cancer in humans. This article envisions a potential clinical use of TOR inhibitors in order to slow aging and delay cancer.

引用

页码：1520 / 1524

页数：5

共 103 条

[41] Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV β-chemokines:: An approach to suppress R5 strains of HIV-1 [J].

Heredia, A ;

Amoroso, A ;

Davis, C ;

Le, N ;

Reardon, E ;

Dominique, JK ;

Klingebiel, E ;

Gallo, RC ;

Redfield, RR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (18) :10411-10416

[42] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[43]

Ikeno Y, 2003, J GERONTOL A-BIOL, V58, P291

[44] Dysregulation of the TSC-mTOR pathway in human disease [J].

Inoki, K ;

Corradetti, MN ;

Guan, KL .

NATURE GENETICS, 2005, 37 (01) :19-24

[45] The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span [J].

Jia, K ;

Chen, D ;

Riddle, DL .

DEVELOPMENT, 2004, 131 (16) :3897-3906

[46] Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes [J].

Johnson, JA ;

Majumdar, SR ;

Simpson, SH ;

Toth, EL .

DIABETES CARE, 2002, 25 (12) :2244-2248

[47] Sirolimus: A ten-year perspective [J].

Kahan, BD .

TRANSPLANTATION PROCEEDINGS, 2004, 36 (01) :71-75

[48] Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia [J].

Kaidi, Abderrahmane ;

Qualtrough, David ;

Williams, Ann C. ;

Paraskeva, Christos .

CANCER RESEARCH, 2006, 66 (13) :6683-6691

[49] Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway [J].

Kapahi, P ;

Zid, BM ;

Harper, T ;

Koslover, D ;

Sapin, V ;

Benzer, S .

CURRENT BIOLOGY, 2004, 14 (10) :885-890

[50] Natural history of renal masses followed expectantly [J].

Kassouf, W ;

Aprikian, AG ;

Laplante, M ;

Tanguay, S .

JOURNAL OF UROLOGY, 2004, 171 (01) :111-113

← 1 2 3 4 5 6 7 8 9 10 →